Table 1.

Baseline and treatment summary sample characteristics.

Baseline characteristics	Control (n = 26)	Mifamurtide (n = 23)	p
Gender M/F (%)	15 (58%)/11 (42%)	15 (65%)/8 (35%)	0.770
Age mean ± SD	14.1 ± 4.4	13.8 ± 4.3	0.824
Histology (%)			~1.0†
Conventional osteoblastic	17 (65%)	15 (65%)
High-grade other	7 (27%)	7 (31%)
Periosteal	2 (8%)	1 (4%)
Site			0.653†
Femur	11	6
Tibia or fibula	5	8
Lower limb – other	2	0
Humerus	2	5
Upper limb – other	3	2
Skull/axial	3	2
Lung unspecific nodules (%)	7 (27%)	11 (48%)	0.151
surgery
Resection‡ R0/R1 (%)	19 (76%)/6 (24%)	20 (87%)/3 (13%)	0.466
Limb‡ sparing/amputation (%)	20 (80%)/5 (20%)	23 (100%)/0 (0%)	0.051
Good/poor response* (%)	14 (64%)/8 (36%)	14 (70%)/6 (30%)	0.750
Follow-up
Median [months]	73.2	42.7
Events (progression/toxicity/death)	12/0/8	1/1/2

p: statistical significance.

^*4 or 3 patients underwent surgical resection before administration of chemotherapy thus their histologic response was not evaluable.

^†Categories were appropriately grouped to enable valid testing.

^‡Surgery was not possible in one patient.